DBV Technologies Announces Change in U.S. Reporting Status and Final Approval of Global Restructuring Process
DBV Technologies Announces Change in U.S. Reporting Status and Final Approval of Global Restructuring Process Montrouge, France, January 7, 2021 DBV Technologies Announces Change in U.S. Reporting Status and Final Approval of Global Restructuring Process DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that it has determined that it now qualifies as a U.S. domestic issuer rather than a foreign private issuer in the United States. As of January 1, 2021, DBV Technologies is subject to U.S. Sec...
Source: globalbankingandfinance.com